Latest Breaking News On - Medtronic private limited - Page 2 : comparemela.com

Mumbai (Maharashtra) [India], August 25 (ANI/BusinessWire India): Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc, today announced the launch of SenSight directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy. Deep brain stimulation (DBS) is a treatment for symptoms of Parkinson's disease, including tremors, stiffness, and trouble walking. Parkinson's disease is a progressive disorder that eventually causes severe disability due to the increasing severity of treatment-resistant motor problems and non-motor symptoms In 2016, it was estimated that 6.1 million people worldwide had Parkinson's disease. The prevalence in India was estimated to be 10 per cent of the global burden, that is, 5.8 lakhs.1 DBS is a therapy in which a small pacemaker-like device sends electrical signals through very thin wires, known as 'leads' to a targeted area in the brain related to the

Ravi gopal varmaRahul aroraMedtronic privateGlobal centerBusinesswire indiaMedtronic private limitedDeep brain stimulationAster hospitalsLead consultant neurosurgeonMovement disorders specialistNeurosciences therapiesMumbai maharashtra indiaUgust 25 ani businesswire india medtronic private limitedA wholly owned subsidiary of medtronic plcOday announced the launch of sensight directional lead system for deep brain stimulation dbs therapy as treatment symptoms associated with movement disorders and epilepsy isa parkinson 39s diseaseNcluding tremors